ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, announced today that it has entered an agreement with Public University Corporation Yokohama City University (YCU) to review a Pseudomonas aeruginosa vaccine, with an exclusive option to license the technology.

This research will formulate YCU’s flagellin-based vaccine candidates with IVT’s DepoVax™ delivery system. The goal is to develop a vaccine that generates a stronger immune response to prevent systemic and local P. aeruginosa infections.

“This vaccine formulation has the potential to generate strong immune responses in immunocompromised individuals susceptible to this pathogen,” said Dr. Marc Mansour, vice president of R&D at IVT.

According to the CDC, Pseudomonas aeruginosa infects immunocompromised patients and accounts for 10% of all hospital-acquired infections. P. aeruginosa infections are often resistant to antibiotics and can be life threatening to people with cancer, cystic fibrosis, severe burns and AIDS.

“There is a vast unmet need for a vaccine that treats individuals infected with Pseudomonas aeruginosa and we are thrilled to work with YCU,” continued Mansour. “This is a milestone for IVT as it establishes our reach into Asia and strengthens our diversification strategy for DepoVax™.”

The potential value of IVT’s proprietary DepoVax™ vaccine delivery technology continues to gather momentum. In 2008, Pfizer Animal Health licensed the technology for two livestock vaccines. Also, recent partnerships with LIAI, NIH, Defence Research & Development Canada and FIT Biotech, have brought the value of Depovax™ into the limelight. For more information visit www.immunovaccine.com.

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future are forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. IVT assumes no responsibility to update forward-looking statements in this press release.

For more information, please contact:
Marc Mansour, VP of R&D
T: (902) 492-1819
mm.ivt@immunovaccine.com

Halifax, Nova Scotia, July 8, 2009